CAS 887650-05-7

Bafetinib

Description:

Bafetinib is a small molecule inhibitor primarily used in the treatment of certain types of cancers, particularly chronic myeloid leukemia (CML). It functions as a selective inhibitor of the BCR-ABL tyrosine kinase, which is a fusion protein that plays a crucial role in the pathogenesis of CML. The chemical structure of Bafetinib includes a pyrimidine core, which is essential for its activity, and it exhibits a high affinity for the ATP-binding site of the BCR-ABL protein. Bafetinib is characterized by its ability to inhibit cell proliferation and induce apoptosis in BCR-ABL-positive cells. Its pharmacokinetic properties include oral bioavailability, and it is metabolized primarily in the liver. Common side effects associated with Bafetinib treatment may include gastrointestinal disturbances, hematological abnormalities, and potential cardiovascular effects. As with many targeted therapies, monitoring for efficacy and adverse effects is crucial during treatment. Overall, Bafetinib represents a significant advancement in the targeted therapy landscape for hematological malignancies.

Formula: C₃₀H₃₁F₃N₈O

Synonyms:

• N-[3-([5,5'-Bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)benzamide
• N-{3-[([5,5'-bipyrimidin]-2-yl)amino]-4-methylphenyl}-4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide

Lyn-IN-1

CAS: 887650-05-7

Lyn-IN-1 (Bafetinib analog) is a selective and potent dual inhibitor of Bcr-Abl and Lyn

Formula: C₃₀H₃₁F₃N₈O

Purity: 97% - 98.02%

Color and Shape: Solid

Molecular weight: 576.62

Ref: TM-T11916

N-[3-([5,5'-Bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[(3s)-3-(dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)benzamide

CAS: 887650-05-7

Formula: C₃₀H₃₁F₃N₈O

Purity: 98%

Color and Shape: Solid

Molecular weight: 576.6153

Ref: IN-DA00GU1B

Lyn-IN-1

CAS: 887650-05-7

Lyn-IN-1

Purity: ≥95%

Molecular weight: 576.62g/mol

Ref: 54-BUP12903